Yazdani Zinat, Mousavi Zahra, Moradabadi Alireza, Hassanshahi Gholamhossein
Department of Hematology and Blood Banking, Kerman University of Medical Sciences, Kerman, Iran.
Department of Hematology and Medical Laboratory Sciences, Iranshahr University of Medical Sciences, Iranshahr, Iran.
Cancer Manag Res. 2020 Mar 24;12:2155-2165. doi: 10.2147/CMAR.S234883. eCollection 2020.
Acute myeloid leukemia (AML) is defined as an aggressive disorder which is described by accumulation of immature malignant cells into the bone marrow. Chemokine-receptor axes are defined as factors involved in AML pathogenesis and prognosis. The chemokine receptor CXCR4 along with its ligand, CXCL12 fit in important players that are actively involved in the cross-talk between leukemia cells and bone marrow microenvironment. Therefore, according to the above introductory comments, in this review article, we have focused on delineating some parts played by CXCL12/CXCR4 axis in various aspects of AML malignancy. Targeting both leukemic and stromal cell interaction is nowadays accepted as a wide and attractive strategy for improving the outcome of treatment in AML in a non-cell autonomous manner. This strategy might be employed in a wide variety of AML patients regardless of their causative mutations. In addition to several potential targets involved in the disruption of malignant leukemic cells from their specific protective niches, compounds which interfere with CXCL12/CXCR4 axis have also been explored in multiple early-phase established clinical trials. Moreover, extensive research programs are exploring novel leading mechanisms for leukemia-stromal interactions that appear to find out novel therapeutic targets within the near future.
急性髓系白血病（AML）被定义为一种侵袭性疾病，其特征是未成熟恶性细胞在骨髓中积聚。趋化因子受体轴被认为是参与AML发病机制和预后的因素。趋化因子受体CXCR4及其配体CXCL12是积极参与白血病细胞与骨髓微环境相互作用的重要因子。因此，根据上述介绍性评论，在这篇综述文章中，我们重点阐述了CXCL12/CXCR4轴在AML恶性肿瘤各个方面所起的一些作用。如今，靶向白血病细胞与基质细胞的相互作用被认为是一种广泛且有吸引力的策略，可通过非细胞自主方式改善AML的治疗效果。无论AML患者的致病突变如何，该策略都可应用于多种AML患者。除了几个参与破坏恶性白血病细胞与其特定保护性微环境的潜在靶点外，干扰CXCL12/CXCR4轴的化合物也已在多个早期既定临床试验中进行了探索。此外，广泛的研究项目正在探索白血病-基质相互作用的新主导机制，似乎在不久的将来会发现新的治疗靶点。
